Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells
Qing-Quan Li, Jing-Da Xu, Wen-Juan Wang, Xi-Xi Cao, Qi Chen, Feng Tang, Zhong-Qing Chen, Xiu-Ping Liu, and Zu-De Xu

Abstract

Purpose: Besides its therapeutic effects, chemotherapeutic agents also enhance the malignancy of treated cancers in clinical situations. Recently, epithelial-mesenchymal transition (EMT) has attracted attention in studies of tumor progression. We aimed to test whether transient Adriamycin treatment induces EMT and apoptosis simultaneously in cancer cells, clarify why the same type of cells responds differentially (i.e., apoptosis, EMT) to Adriamycin treatment, and elucidate the role of Twist1, the master regulator of EMT, in this process.

Experimental Design: In unsynchronized MCF7 cells or cells synchronized at different phases, apoptosis, EMT, and concurrent events [multidrug resistance (MDR) and tumor invasion] after Adriamycin or Twist1 small interfering RNA treatment were examined in vitro and in vivo. The Adriamycin-induced Twist1 expression and the interaction of Twist1 with p53-Mdm2 were examined by immunoblotting and immunoprecipitation, respectively.

Results: We showed in vitro that Adriamycin induced EMT and apoptosis simultaneously in a cell cycle-dependent manner. Only the cells undergoing EMT displayed enhanced invasion and MDR. Twist1 depletion completely blocked the mesenchymal transformation, partially reversed MDR, and greatly abolished invasion induced by Adriamycin. Also, we confirmed in vivo that Twist1 RNA interference improved the efficacy of Adriamycin for breast cancers. Further, Twist1 reduction in Adriamycin-treated cells promoted p53-dependent p21 induction and disrupted the association of p53 with Mdm2.

Conclusions: Our studies show the diverse responses to Adriamycin treatment in cells at different phases, suggest an unrecognized role of EMT in regulating MDR and invasion, and show the efficacy of Twist1 RNA interference in Adriamycin-based chemotherapies for breast cancer.

The resistance of tumor cells to multiple chemotherapeutic agents, a mechanism termed multidrug resistance (MDR), is a major obstacle to the success of cancer chemotherapy and has been closely associated with treatment failure (1). Previous research reported that transient exposure to chemotherapeutic drugs induces P-glycoprotein (P-gp) and MDR1 mRNA expression in subpopulations of treated cancer cells, and the cells overexpressing P-gp display variations in invasive and metastatic behavior (2, 3). However, the detailed mechanism(s) underlying these phenomena still remains unclear.

The cellular transformations that modulate these capabilities seem analogous to some of the changes required for the acquisition of more aggressive phenotypes. Epithelial-mesenchymal transition (EMT), which disaggregates structured epithelial units to enable cell motility and morphogenesis in embryonic development, has attracted attention in studies of tumor progression (4–7). The most prominent characteristic of EMT is the morphologic alteration from epithelial to mesenchymal, which is often accompanied by the dissolution of epithelial tight junctions, loss of cell adhesion, down-regulated expression of some epithelial markers as well as the acquisition of migratory and invasive properties. Along with these changes, the cytoskeleton of the cells rearranges to render the cells with a spindle-like morphology (8). EMT is a complex process involving the genetic mutations that confer cancer developmental and malignant phenotypes and is critically linked with up-regulated invasion, metastasis, and angiogenesis (9, 10). The normal cellular processes involved in EMT during development are thought to play key roles in the multiphase evolution from a benign to an invasive malignant tumor (11).

The basic helix-loop-helix transcription factor Twist1 is a major regulator of mesenchymal phenotypes (12). It has also been recently identified as capable of mediating carcinoma...
Adriamycin (25 ng/mL) was added to culture with nocodazole (0.1 ng/mL; Sigma) for at least 20 h. After the treatment, floating and attached cells were harvested, washed with PBS, fixed in 70% ethanol overnight at 4°C, and stained with 50 mg/ml propidium iodide (Sigma). The sub-G1 peak (DNA content <2N) was measured with FACScan Flow Cytometry (Becton Dickinson Labware) and was analyzed by Cell Quest software.

Western blotting and co-immunoprecipitation. Total protein was extracted from cells with the use of RIPA lysis buffer (Santa Cruz Biotechnology). For Western blots, 50 μg of protein extract per lane were electrophoresed, transferred to polyvinylidene fluoride membranes, and incubated overnight with antibodies against E-cadherin (Santa Cruz Biotechnology, Inc.), Twist1 (Santa Cruz Biotechnology), p53 (Sigma), p21 (Sigma), and Mdm2 (Santa Cruz Biotechnology). The membranes were treated with the appropriate Alexa Fluor 700/800 nm–conjugated secondary antibodies (Invitrogen) and were analyzed with the use of the Odyssey Infrared Imaging System (Li-Cor BioSciences). For co-immunoprecipitation, 1 mg of protein lysate from each sample was incubated with 2 μg of anti-Twist1, p53, or Mdm2 overnight at 4°C. Then immunoblotting detections were done as described above.

Drug sensitivity assay. To assess their multidrug chemosensitivity, the cells under disposal and their corresponding controls were plated in 96-well plates at a density of 10^4 cells per well and further incubated for 24 h. The medium was then removed and replaced with fresh medium containing paclitaxel (Sigma), vincristine (Sigma), and bleomycin (Alexis Biochemicals) at varying concentrations for another 48 h. After that, cells were stained with 20 μl sterile 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye at 37°C for 4 h followed by removal of culture medium and mixing of 150 μl DMSO thoroughly for 10 min. Spectrometric absorbance at 490 nm was measured with a microplate reader. Each group contained 3 wells and was repeated 3×. The half maximal inhibitory concentration value was determined by the dose of drug that causes 50% cell viability.

Tumor cell in vitro invasion assays. Transwell plates (Corning Costar) were coated with basement membrane Matrigel (0.8 mg/ml; Becton Dickinson) for 4 h at 37°C. The cells were detached with trypsin and washed with serum-containing medium. Cells (1x10^5) were added to the upper chamber in a total volume of 100 μl of serum-free medium supplemented with Adriamycin (25 μg/ml). The lower chamber contained 600 μl conditioned medium (incubating NIH3T3 cells in serum-free RPMI 1640 medium for 24 h) as chemoattractant. After 48 h, cells that migrated through the permeable membrane were fixed in methanol, stained with H&E, and counted. Each assay was done in triplicate and repeated 3×.

Inhibition of Twist1 expression by RNAi. To generate Adriamycin-induced Twist1-negative MCF7 cells, Twist-targeted RNAi experiments were done. Cells (2x10^5) were seeded in 6-well plates in triplicates and, after overnight incubation, the cells were transfected with various concentrations of small interfering RNA (siRNA) before Adriamycin treatment in serum-free Opti-MEM medium with the use of HiPerFect (Qiagen) as suggested by the manufacturer’s instructions. After another 36 h of incubation with Adriamycin, total protein was extracted and gene expression was determined by quantitative real-time PCR. In all cases, about 60–70% of the expected level of Twist1 mRNA was inhibited.

Twist1 siRNA–transfected cells invasion assay. Cells were tripanized and resuspended in serum-free Opti-MEM ( Gibco). From this single cell population, 10,000 cells were plated onto permeable inserts of transwell plates. For each experiment, triplicates were done. After 24 h, cells that migrated through the permeable membrane were fixed in methanol, stained with H&E, and counted. Each assay was done in triplicate and repeated 3×.
Adriamycin-Induced EMT and Concurrent Events

Results

Adriamycin induced EMT and apoptosis simultaneously in cancer cells. When the morphology of routinely cultured MCF7 cells treated with or without Adriamycin was examined by microscopy, we observed that, whereas MCF7 cells grew as tightly-packed colonies characteristic of epithelial cells and showed limited cell spreading, cells treated with Adriamycin seemed flattened and actively spreading, and had lost the majority of their cell-cell contacts (Fig. 1A). Similar effects were also observed in other epithelial cancer cells (HuH7, BxPC-3, and DLD-1; Supplementary Fig. S1A). These phenomena were associated with decreased expression of E-cadherin and CK19, and up-regulation of α-SMA, vimentin (Fig. 1B and Supplementary Fig. S1B). Because the loss of epithelial markers, including E-cadherin, cytokeratin, zonula occludens-1, and a corresponding increase in mesenchymal markers, such as vimentin, SMA, and/or fibroblast-specific protein 1, are the critical events signaling loss of the epithelial phenotype and commencement of mesenchymalization (5, 18–20), it can be concluded that Adriamycin induces EMT in epithelial cancer cells.

In our further studies, EMT induction was observed along with Adriamycin-induced cell damage. After incubation with Adriamycin for 72 hours, the percentage of cells undergoing apoptosis was significantly higher than that in the control group (Table 1 and Supplementary Fig. S1C). Moreover, drug-induced apoptosis was also detected by DNA fragmentation assays (Fig. 1C and Supplementary Fig. S1D).

Adriamycin treatment led to MDR in cancer cells, accompanied by enhanced invasive phenotype. Exposure of MCF7 cells to Adriamycin for 36 hours caused P-gp protein to become detectable by western blotting, and similar effects were

Fig. 1. Adriamycin induces apoptosis, EMT, and concurrent events in cancer cells. Cells were treated with or without Adriamycin (25 μg/mL) for 36 h for EMT analysis or 72 h for apoptotic analysis. A, EMT was examined by phase contrast photomicrographs (×100 magnification; bar, 10 μm). B, western blotting of E-cadherin, CK19, vimentin, and α-SMA was assessed. C, DNA was extracted and analyzed by 1.5% agarose gel electrophoresis. D, endogenous P-gp expression was measured by western blotting, and in vitro invasion assays were done. The number of invaded cells was evaluated in three fields for each experimental group and was averaged. Statistical analysis was done with Dunnett’s test. **, P<0.05 versus control cells.
observed in other epithelial cancer cells (Fig. 1D and Supplementary Fig. S1E). Also, as reported in Table 1, Adriamycin-treated cells showed increased resistance to both P-gp substrates (vincristine, paclitaxel) and a non–P-gp substrate (bleomycin). Thus, Adriamycin exposure led to a uniform decrease in drug sensitivity independent of whether the agents could be transported by P-gp.

The ability of Adriamycin-exposed MCF7 cells to invade through an artificial basement membrane (Matrigel) was assessed by *in vitro* invasion assay as described above. After

### Table 1. IC₅₀ (paclitaxel, vincristine, bleomycin), apoptosis rate, and caspase activity in MCF7 cells at different phases; cells transfected with Twist siRNA or pCMV-Twist1; and cells pretreated with PFT-α after transient Adriamycin exposure

<table>
<thead>
<tr>
<th>Drugs</th>
<th>MCF7</th>
<th>Adriamycin-treated MCF7</th>
<th>Adriamycin-treated MCF7 synchronized at G₁/S phase</th>
<th>Adriamycin-treated MCF7 synchronized at G₂/M phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paclitaxel</td>
<td>0.0156 ± 0.0183</td>
<td>0.7562 ± 0.0238*</td>
<td>1.1365 ± 0.0421*</td>
<td>0.0103 ± 0.0056</td>
</tr>
<tr>
<td>Vincristine</td>
<td>0.3286 ± 0.0931</td>
<td>9.2321 ± 0.3561*</td>
<td>11.5638 ± 0.3397*</td>
<td>0.1867 ± 0.0048</td>
</tr>
<tr>
<td>Bleomycin</td>
<td>0.5644 ± 0.0339</td>
<td>4.8621 ± 0.3723*</td>
<td>5.2139 ± 0.2589*</td>
<td>0.3742 ± 0.0158</td>
</tr>
<tr>
<td>Apoptosis rate</td>
<td>0.0151 ± 0.0007</td>
<td>0.5239 ± 0.0143*</td>
<td>0.1419 ± 0.0051</td>
<td>0.8862 ± 0.0287*</td>
</tr>
<tr>
<td>Caspase activity (fold increase)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cas-1 (substrate IV)</td>
<td>1</td>
<td>2.3 ± 0.23*</td>
<td>1.21 ± 0.14</td>
<td>3.77 ± 0.34*</td>
</tr>
<tr>
<td>Cas-1 (substrate VII)</td>
<td>1</td>
<td>1.8 ± 0.05</td>
<td>1.27 ± 0.13</td>
<td>4.02 ± 0.39*</td>
</tr>
<tr>
<td>Cas-3</td>
<td>1</td>
<td>2.6 ± 0.21*</td>
<td>1.29 ± 0.11</td>
<td>6.38 ± 0.40*</td>
</tr>
<tr>
<td>Cas-6</td>
<td>1</td>
<td>2.9 ± 0.16*</td>
<td>1.20 ± 0.17</td>
<td>6.29 ± 0.33*</td>
</tr>
<tr>
<td>Cas-8</td>
<td>1</td>
<td>1.3 ± 0.09</td>
<td>1.34 ± 0.12</td>
<td>5.91 ± 0.38*</td>
</tr>
</tbody>
</table>

**NOTE:** IC₅₀ values were expressed in μmol/L. Cell apoptosis rate was evaluated by flow cytometry. Caspase activity in nontreated cells was set as 1. Each assay was done in triplicate and repeated in triplicate, and all data were presented with mean ± SE. SDs for all of the experiments done in triplicate were <5%. Abbreviations: IC₅₀, half maximal inhibitory concentration; dsRNA, double-stranded RNA; PFT-α, pifithrin-α.

*P < 0.05 versus control cells.

Fig. 2. Adriamycin-induced EMT and apoptosis are cell cycle dependent. Nonsynchronized cells and cells synchronized at G₁/S or G₂/M phase were treated with Adriamycin for the indicated times. A, EMT was examined by morphologic change (×200 magnification; bar, 10 μm). B, western blotting of E-cadherin, CK19, vimentin, and α-SMA was assessed. C, Adriamycin-induced P-gp expression and *in vitro* invasive potentials of synchronized cells in the presence or absence of Adriamycin were also determined. Quantification and statistical analyses were done on three independent experiments. **, P < 0.05 versus control cells.
48 hours of culture, low numbers of MCF7 cells in the control group were observed to invade through the Matrigel. In contrast, when cultured in the presence of Adriamycin, the number of cells invading through the matrix was significantly greater (Fig. 1D); similar effects were also observed in other epithelial cancer cells (Supplementary Fig. S1E). In repeated invasion assays with different cancer cell lines, the invasiveness of the drug-exposed cells was found to be an average of 2.3-fold to 6.2-fold greater than that of the control group.

Adriamycin-induced apoptosis and EMT were cell cycle–dependent in breast cancer cells. Adriamycin induced concurrent but different events (EMT and apoptosis) in the same type of cells. To investigate the underlying mechanism, we examined the contribution of cell cycle state. We synchronized MCF7 cells at either G1/S or G2/M phase and examined Adriamycin-induced effects. As shown in Fig. 2A, Adriamycin induced morphologic changes in nonsynchronized cells and those synchronized at G1/S phase, whereas it seemed to induce apoptosis in cells synchronized at G2/M phase. To better characterize Adriamycin-induced EMT, we assessed the changes of tight junctions and cytoskeleton by immunofluorescent staining of zonula occludens-1 and α-actin, respectively.

**Table 1.** IC50 (paclitaxel, vincristine, bleomycin), apoptosis rate, and caspase activity in MCF7 cells at different phases; cells transfected with Twist siRNA or pCMV-Twist1; and cells pretreated with PFT-α after transient Adriamycin exposure (Cont’d)

<table>
<thead>
<tr>
<th>Adriamycin-treated dsRNA-transfected MCF7</th>
<th>Adriamycin-treated Twist1 siRNA–transfected MCF7</th>
<th>Adriamycin-treated pCMV-transfected MCF7</th>
<th>Adriamycin-treated pCMV-Twist1–transfected MCF7</th>
<th>PFT-α–pretreated MCF7</th>
<th>Adriamycin-treated PFT-α–pretreated MCF7</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.7964 ± 0.03581</td>
<td>*0.2492 ± 0.0351</td>
<td>8.9637 ± 0.2886</td>
<td>*4.3688 ± 0.5294</td>
<td>4.6630 ± 0.3051</td>
<td>*1.6197 ± 0.3513</td>
</tr>
<tr>
<td>4.6630 ± 0.3051</td>
<td>*0.8239 ± 0.0284</td>
<td>*0.4933 ± 0.0122</td>
<td>*0.5367 ± 0.018</td>
<td>0.0525 ± 0.009</td>
<td>0.0293 ± 0.0004</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0622 ± 0.0003</td>
</tr>
<tr>
<td>*2.18 ± 0.25</td>
<td>*4.29 ± 0.36</td>
<td>*2.18 ± 0.25</td>
<td>1.23 ± 0.28</td>
<td>1.07 ± 0.08</td>
<td>1.04 ± 0.04</td>
</tr>
<tr>
<td>1.75 ± 0.14</td>
<td>*4.56 ± 0.38</td>
<td>1.75 ± 0.14</td>
<td>1.86 ± 0.17</td>
<td>1.15 ± 0.09</td>
<td>1.08 ± 0.15</td>
</tr>
<tr>
<td>*2.62 ± 0.27</td>
<td>*7.21 ± 0.45</td>
<td>*2.62 ± 0.27</td>
<td>1.55 ± 0.20</td>
<td>1.03 ± 0.10</td>
<td>1.05 ± 0.12</td>
</tr>
<tr>
<td>*2.98 ± 0.30</td>
<td>*6.98 ± 0.41</td>
<td>*2.98 ± 0.30</td>
<td>1.70 ± 0.26</td>
<td>1.00 ± 0.11</td>
<td>1.13 ± 0.07</td>
</tr>
<tr>
<td>1.30 ± 0.11</td>
<td>*5.44 ± 0.33</td>
<td>1.30 ± 0.11</td>
<td>1.25 ± 0.13</td>
<td>1.11 ± 0.06</td>
<td>1.09 ± 0.09</td>
</tr>
</tbody>
</table>

Fig. 3. Twist1 is involved in Adriamycin-induced EMT and concurrent events. A, time course and dose effect of Adriamycin-induced Twist1 expression in unsynchronized cell or cells synchronized at different phases. Cells transfected with control double-stranded RNA or Twist1 siRNA were treated with Adriamycin (25 μg/mL) for 36 h. EMT was examined by morphologic change (×100 magnification; bar, 10 μm) B, western blotting of E-cadherin, CK19, vimentin, and α-SMA were assessed (C). D, effects of Twist1 depletion on Adriamycin-induced P-gp expression and increased invasive potentials were determined by western blotting and in vitro invasion assays, respectively. **: P < 0.05 versus control cells.

www.aacrjournals.org Clin Cancer Res 2009;15(8) April 15, 2009 2661
Downloaded from clincancerres.aacrjournals.org on April 10, 2017. © 2009 American Association for Cancer Research.
Supplementary Fig. S2 shows that Adriamycin induced the loss of tight junction and the rearrangement of cytoskeleton in nonsynchronized cells and cells at G1/S phase but not in cells at G2/M phase. Correspondingly, increased expression of α-SMA and vimentin, and down-regulation of E-cadherin and CK19 were also observed in nonsynchronized cells and cells at G1/S phase (Fig. 2B). Meanwhile, Adriamycin tended to raise the apoptosis rate and caspase activity significantly only in cells at G2/M phase (Table 1). These results clearly indicate that Adriamycin-induced apoptosis and EMT are related to the cell cycle state: apoptosis is induced mostly in cells at G2/M phase, whereas EMT occurs only in cells at G1/S phase.

**Only cells undergoing EMT displayed MDR and elevated invasive abilities.** As shown in Fig. 2C, Adriamycin induced P-gp expression in nonsynchronized MCF7 cells or those synchronized at G1/S phase but not in cells at G2/M phase. Corresponding results were observed in drug sensitivity assays (Table 1). Adriamycin also promoted *in vitro* invasion in nonsynchronized cells or those at G1/S phase (Fig. 2C). The reduced number of invading cells synchronized at G2/M phase could be mainly attributed to the drug-induced apoptosis.

**Twist1 was identified as the key point in the process of Adriamycin-induced EMT and concurrent events.** We next explored potential cellular events involved in Adriamycin-induced apoptosis and EMT. We found that Adriamycin induced Twist1 expression in both a time-dependent and a dose-dependent manner (Fig. 3A), whereas no similar effects were detected on other master regulators of EMT, such as Snail, Slug, and SIP1 (refs. 21–23; data not shown). Moreover, we observed that the appearance of Twist1 expression is ahead of morphologic changes. Additional experiments showed that Adriamycin-induced Twist1 expression could only be detected in cells at G1/S but not G2/M phase (Fig. 3A).

To test whether the up-regulation of Twist1 contributed to Adriamycin-induced responses, the effects of specific Twist1 siRNA on these events were evaluated. We used siRNA duplexes specific for human Twist1 as well as scrambled double-stranded RNA unrelated to any known gene as a control. The most effective concentration of siRNA tested (10 nmol/L) yielded a 92% Twist1 depletion (data not shown) and was used to examine the effects of Adriamycin on Twist1-negative cells. According to the changes in cell morphology (Fig. 3B) and the intracellular distribution of zonula occludens-1 and β-actin (Supplementary Fig. S3), Twist1 suppression blocked the drug-induced EMT, whereas the double-stranded RNA control showed no such effects. In line with these results, Twist1 siRNA reversed the effects of Adriamycin on E-cadherin, CK19, α-SMA, and vimentin expression (Fig. 3C). Also, we investigated whether Twist1 is involved in Adriamycin-induced apoptosis. Twist1 siRNA enhanced the apoptosis rate and caspase activity in response to Adriamycin treatment. On the contrary, this process was reversed by overexpression of Twist1 in Adriamycin-treated cells (Table 1).

Furthermore, Twist1 suppression prevented the drug-induced P-gp expression (Fig. 3D), concomitant with partial reduction in resistance to multiple agents (Table 1). This partial reduction in MDR implied that there may exist some other mechanism(s), in addition to Twist1, involved in Adriamycin-induced MDR. Twist1 siRNA also greatly decreased the invasive rate (Fig. 3D), which could be mainly ascribed to the elevated apoptosis rate.

**Enhanced inhibition of tumor growth invasion and prolongation of survival in mice bearing breast tumors by combined pSilencer-twist and Adriamycin treatment.** To improve and extend the results of *in vitro* experiments, we established a breast cancer model that mimics the clinical features. Tumor homogenates were subjected to western blot analysis for confirming Twist1 inhibition by pSilencer-twist treatment (data not shown). The antitumor effects of Adriamycin and pSilencer-twist were determined on MCF7 breast tumors. A significant growth inhibitory effect was observed in the treated groups as compared with the control groups. Indeed, after 35 days of treatment with Adriamycin in MCF7 and MCF7/pSilencer-twist tumors, the mean tumor volume was reduced by

---

**Fig. 4.** Antitumor effects of Adriamycin are enhanced by pSilencer-twist. MCF7 cells transfected with pSilencer-twist or pSilencer were implanted s.c. When tumors reached an average volume of 80 mm³, mice (15 per group) were treated with Adriamycin (13.5 mg/kg; 3× weekly) or 0.1 mL normal saline (pH 7.4; 3× weekly) for 35 d. Five mice were included in each group. Tumor volume (A) and weight (B) were measured at 35 d after inoculation with Adriamycin or saline. C, cumulative survival rate of nude mice implanted s.c. with MCF7 tumor cells. The survival curve was plotted according to the method of Kaplan-Meier (*n* = 10). ***, *P < 0.005 versus control cells.**
30.6% ($P > 0.05$) and 76.8% ($P < 0.05$; Fig. 4A), respectively, whereas the mean tumor weight was decreased by 42.4% ($P < 0.05$) and 78.2% ($P < 0.05$; Fig. 4B), respectively. At postmortem examination, no tumor metastasis was seen 35 days after s.c. injection of Adriamycin in MCF7/pSilencer-twist tumors, whereas pulmonary and lymphonodi metastasis foci could be found in control mice 20 days after receiving treatment of Adriamycin (data not shown). Seventeen weeks after treatment, the Kaplan-Meier plot assessment showed a significant prolongation of surviving mice bearing breast tumors after combined treatment (Adriamycin+pSilencer-twist). Figure 4C shows that the median survival time of untreated mice (PBS) was 48 days. In contrast, the median survival time of Adriamycin+pSilencer-twist–treated mice was significantly longer (110 days) than that of mice treated with Adriamycin or pSilencer-twist alone (77 and 48 days, respectively).

**Twist1 dictated p53 response induced by Adriamycin via Mdm2 interaction.** Adriamycin is a chemotherapeutic agent that is known to activate p53. After pretreatment with 20 μg/mL pifithrin-α (a small molecule inhibitor of p53 activity) for 4 hours, the apoptosis rate in Adriamycin-treated MCF7 cells was significantly lower (6.22%) than that in the control cells (52.39%), and so was the caspase activity (Table 1). Meanwhile, the number of cells undergoing EMT increased under the same condition (Fig. 5A), suggesting that Adriamycin induces apoptosis via a p53-dependent pathway in MCF7 cells. We also noted that after Adriamycin treatment, the induction of p53 and its target (p21) was markedly augmented in nonsynchronized cells or those at G2/M phase, whereas relatively less induction was noted in cells synchronized at G1/S phase (Fig. 5B).

To examine the role of Twist1 in p53 activation, we introduced Twist1 siRNA into MCF7 cells and determined whether the reduced level of Twist1 affects the induction of p53 and p21 after Adriamycin exposure. In cells unsynchronized or synchronized at G1/S phase, we observed that Twist1 depletion enhanced p53 and p21 production strikingly under the treatment of Adriamycin (Fig. 5B). In contrast, because Adriamycin did not induce Twist1 expression in cells at G2/M phase, Twist1 siRNA had no such effects (data not shown).

The data presented above indicate that the expression level of Twist1 has significant effects on p53 and p21 induction. To obtain insight into the molecular mechanism of how such effects were achieved, we examined whether Adriamycin affects the physical interaction among p53, Mdm2, and Twist1. To avoid potential degradation of p53 via Mdm2-dependent ubiquitination, cells were treated with MG132, a proteasome inhibitor, before the interactions were examined by immunoprecipitation analyses. Figure 5C shows that the p53-Mdm2-Twist1 complex formed after Adriamycin exposure. Adriamycin treatment increased the association of p53 with Twist1 and Mdm2. On the other hand, Twist1 depletion decreased the formation of the p53-Mdm2 complex (Fig. 5C); from this
we inferred that Twist1 promotes the interaction of Mdm2 with p53.

**Discussion**

Chemotherapy is a systemic treatment involving the use of chemical agents to stop cancer cells from growing. Although chemotherapy effectively eliminates cancer cells, its opposite effects that enhance the malignancy of the treated cancers have also been reported (2, 24, 25). In a clinical situation, acquired drug resistance and enhanced metastasis frequently follow chemotherapeutic regimens, leading to treatment failure (i.e., cancer recurrence) in tumor patients. It seems that the syngeneic tumor cells may respond differently to the same chemotherapeutic drug. However, the detailed mechanism(s) underlying this phenomenon still remains unclear.

In the present study, we found that, except for Adriamycin-induced apoptosis, cancer cells exposed to Adriamycin transiently also showed EMT consistent with phenotypic changes, including MDR and enhanced invasive abilities. Adriamycin-induced EMT was first observed by morphologic changes, further validated by hallmarks of EMT. Recent publications implied that this is the case in chronic resistance to chemotherapeutic agents. Kajiyama et al. observed cellular morphology, motility, and molecular changes consistent with EMT in human stable paclitaxel-resistant epithelial ovarian carcinoma cells and suggested a possible link between chronic paclitaxel-resistance and EMT induction (26). Our results reflect the emergence of EMT after 36 hours of Adriamycin treatment. Therefore, it can be deduced that during the process of chemotherapy, EMT emerges at the very start. In view of the Adriamycin-induced concomitant EMT and apoptosis, a question was raised: why did Adriamycin induce the death of only a portion of cells but not all after a certain period of treatment? We hypothesized that, in response to Adriamycin treatment, some cells underwent the process of EMT and survived, thereby becoming the stable cell line resistant to chemotherapeutic agents at last.

Then another question arose: why, under the same experimental conditions, did the same type of cells respond differentially to Adriamycin treatment? The most likely factor that determines the various responses, and thus the different fates of cells, to the same stimuli should be differences that lie in the cells themselves. Because emerging evidence has shown that cell cycle state is an important factor for cellular responses to extracellular stimuli (27), we considered that there might be a relationship between cell cycle progression and Adriamycin-induced effects. We observed Adriamycin-induced EMT in both unsynchronized cells and those synchronized at G1/S phase, whereas a dramatic increase was observed in the apoptosis rate of cells synchronized at G2/M phase. These results indicated that Adriamycin-induced apoptosis and EMT are closely related with the cell cycle stage. We also showed that only cells undergoing EMT exhibited two malignant phenotypes, promoted invasion and MDR, which have been studied extensively and functionally linked with each other (28–32). The two phenotypes were coregulated and associated with EMT in cancers. In particular, in regular cell cultures without synchronization, cells are highly heterogeneous in terms of cell cycle phases and therefore respond differentially to Adriamycin, including apoptosis and EMT. For cells at G1/S phase, Adriamycin promotes EMT and tumor progression characterized by acquisition of MDR and promoted invasive potential.

Our work also revealed that Twist1 may assume a dual role because it has intrinsic potential effects on EMT as well as an antiapoptotic function. On one hand, we found that Adriamycin induced Twist1 expression only in unsynchronized cells or cells synchronized at G1/S phase, consistent with the emergence of EMT. Twist1 RNAi largely inhibited EMT induction, partially reversed MDR phenotype, and obviously abolished increased cell invasion of MCF7 cells. Combined Twist1 siRNA and Adriamycin treatment prevented tumor growth in vivo invasion and prolonged survival in mice bearing breast tumors. Consistent with its function in EMT, Twist1 was observed to be correlated with metastasis in various cancers, including ovarian, prostate, and nasopharyngeal cancers (33–36). Our data implicated that up-regulation of Twist1 seems to be a crucial event in EMT from low-grade to higher-grade malignant tumor cells. The concomitant use of Twist1 siRNA during chemotherapy can be a potential therapeutic approach to improve the efficacy of Adriamycin for breast cancer. Apart from these, because Twist1 is a master EMT regulator, it is reasonable to believe that acquisition of the malignant phenotypes after Adriamycin treatment is the byproduct during the process of EMT.

On the other hand, we found that Twist1 overexpression prevented cells from undergoing apoptosis in response to Adriamycin treatment. Twist1 has been reported to inhibit oncogene-dependent and p53-dependent cell death via inhibiting p14ARF expression or Mdm2 activity (37, 38). Adriamycin belongs to the DNA-damaging agent that provokes a p53 response (39). We first showed the formation of p53-Mdm2-Twist1 complex in Adriamycin-treated cells synchronized at G1/S phase. The regulation of p53-Twist1 interaction by external stimuli mainly reflects its effect on p53-Mdm2 interaction. Remarkably, the levels of the p53-Mdm2-Twist1 complex formed after Adriamycin treatment showed good correlation with the extent of Twist1-dependent inhibition of p21 activation under this condition. Therefore, it is likely that distinct effects of Adriamycin on p53 activation, at least in part, depend on how it impacts p53-Mdm2-Twist1 interaction. Because no Twist1 expression was observed in cells at G2/M phase after Adriamycin treatment, MCF7 cells remained susceptible to the chemotherapeutic agent. Taken together with the data of flow cytometry, which showed that Twist1 RNAi raised the apoptosis rate of Adriamycin-treated MCF7 cells, we inferred that Twist1 depletion effectively enhances chemosensitivity to Adriamycin through disruption of the p53-Mdm2-Twist1 complex.

In summary, our data begin to clarify the mechanism involved in differential effects (i.e., apoptosis, EMT, and enhanced malignancy) in response to short-term Adriamycin treatment in cancers and also make evident the observed relationships between the differential effects and cell cycle state. It seems that suppression of the molecule associated with EMT, such as Twist1, could be an effective target for abolishing the opposite effects during clinical treatment of breast cancers in particular.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.
References

Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells

Qing-Quan Li, Jing-Da Xu, Wen-Juan Wang, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/15/8/2657

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2009/04/01/1078-0432.CCR-08-2372.DC1

Cited articles
This article cites 39 articles, 16 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/8/2657.html#ref-list-1

Citing articles
This article has been cited by 16 HighWire-hosted articles. Access the articles at:
/content/15/8/2657.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.